Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mononuclear stem cells
- Development stage
- Discontinued
- Lead developer
- Novo Cellular Medicine Institute
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal, Intravenous
01
Overview
Autologous bone marrow-derived mononuclear stem cells (BM-MNC) are a heterogeneous population of cells harvested from a patient's own bone marrow, containing hematopoietic stem cells, mesenchymal stem cells, and endothelial progenitor cells. Developed by Novo Cellular Medicine Institute LLP, this cell therapy was investigated for the treatment of relapsing-remitting multiple sclerosis (RRMS) in a Phase I/II clinical trial (NCT01373528). The treatment protocol involved the administration of these cells via intrathecal and intravenous routes, often in conjunction with "liberation therapy"—a surgical procedure involving balloon angioplasty of the internal jugular and/or azygos veins intended to address chronic cerebrospinal venous insufficiency (CCSVI). The therapeutic rationale is based on the cells' ability to migrate to sites of injury, modulate the immune response by secreting anti-inflammatory cytokines, and provide neurotrophic support to promote myelin repair and neuroprotection.
- Other names
- BM-MNCautologous BM-MNC
Beyond the preview
Go deeper on autologous bone marrow-derived mononuclear stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mononuclear stem cells.